Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / July 20, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent to withdraw application filings with both the European Medicines Agency (EMA) and the Japanese Regulatory Agency (PMDA) for abicipar...
Read more









